Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective Open Label Study to Evaluate Vasomotor Symptoms Control and Bleeding Patterns With a Continuous Regimen of a New Progestin Trimegestone 0.125 mg and 17 b Estradiol 1 mg (Totelle),as HT on Postmenopausal Women

NCT00195455 is registered in ClinicalTrials.gov with Wyeth is now a wholly owned subsidiary of Pfizer as lead sponsor.

NCT NCT00195455
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00195455 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective Open Label Study to Evaluate Vasomotor Symptoms Control and Bleeding Patterns With a Continuous Regimen of a New Progestin Trimegestone 0.125 mg and 17 b Estradiol 1 mg (Totelle),as HT on Postmenopausal Women
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Phase
Phase 4
Overall status
Completed
Start date
February 28, 2005
Completion date
March 31, 2007
Enrollment
133 (estimated)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

postmenopause